Elizabeth Ofili to Treatment Outcome
This is a "connection" page, showing publications Elizabeth Ofili has written about Treatment Outcome.
Connection Strength
0.540
-
Ofili EO, Pemu PE, Quarshie A, Mensah EA, Rollins L, Ojutalayo F, McCaslin A, Clair BS. DEMOCRATIZING DISCOVERY HEALTH WITH N=Me. Trans Am Clin Climatol Assoc. 2018; 129:215-234.
Score: 0.119
-
Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther. 2013 Jan; 20(1):2-12.
Score: 0.084
-
Pemu PE, Quarshie AQ, Josiah-Willock R, Ojutalayo FO, Alema-Mensah E, Ofili EO. Socio-demographic psychosocial and clinical characteristics of participants in e-HealthyStrides?: an interactive ehealth program to improve diabetes self-management skills. J Health Care Poor Underserved. 2011; 22(4 Suppl):146-64.
Score: 0.073
-
Igho-Pemu P, Quarshie A, Oduwole A, Lapu-Bula R, Mayberry R, Obialo C, Gibbons GH, Ofili E. Morehouse Community Physicians Network (CPN) hypertension registry: patterns of care and opportunities for targeted medical education. Ethn Dis. 2005; 15(4 Suppl 5):S5-120-3.
Score: 0.048
-
Obialo CI, Ofili EO, Norris KC. Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation. Int J Environ Res Public Health. 2018 12 04; 15(12).
Score: 0.032
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
Score: 0.025
-
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, D?vila-Rom?n VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310(23):2533-43.
Score: 0.022
-
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27; 309(12):1268-77.
Score: 0.021
-
Floyd B, Chandra P, Hall S, Phillips C, Alema-Mensah E, Strayhorn G, Ofili EO, Umpierrez GE. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol. 2012 Sep 01; 6(5):1094-102.
Score: 0.020
-
Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010 Aug; 28(8):1761-9.
Score: 0.018
-
Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
Score: 0.015
-
Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007 Apr 03; 115(13):1747-53.
Score: 0.014
-
Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, Cohn JN. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006 Dec 05; 48(11):2263-7.
Score: 0.014
-
Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.013
-
Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.013
-
Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002 Jun; 8(3):128-35.
Score: 0.010